Previous 10 | Next 10 |
Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex’s R&D efforts during the last two years, was successfully completed in Q1 2022, twelve months ahead of schedule Frozen formulation Allocetra™ is expected to vastly improve...
Nes-Ziona, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of Israeli Patent Number 255119 entitled, “Therapeutic Pooled...
Dr. Galamidi joins Enlivex after 10 years at Gamida Cell Ltd., where she most recently served as Vice President of Clinical Development At Gamida Cell, Dr. Galamidi led clinical development for omidubicel, a cell therapy that successfully completed Phase III in 2020 A Biologic...
** Management to participate in a panel discussion: “Innovative Approaches to Cell Therapy for Oncology,” which is taking place on Friday, January 7 th , at 8:30 AM ET ** ** Panelists to discuss how their cell-based technologies, including, CAR-T cells, CAR-NK cells, T...
Nes-Ziona, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the Company’s preclinical and clinical data, st...
Nes-Ziona, Israel, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the Company’s preclinical and clinical data, st...
Nes-Ziona, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new p...
Envilex Therapeutics (NASDAQ:ENLV): Q3 Net Loss of $4.32M Cash, cash equivalents, and marketable securities of $87.6M. Press Release For further details see: Envilex Therapeutics reports Q3 results
Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating Allocetra TM in severe and critical COVID-19 patients with ARDS Received authorization to expand ongoing sepsis and COVID-19 trials into Spain Initiated design and construction process for a new...
Enlivex Therapeutics (NASDAQ:ENLV) is trading ~6.1% higher in the pre-market after the company disclosed that the Spanish Agency of Medicines and Medical Devices (AEMPS) cleared the expansion of its Phase IIb trial for Allocetra in COVID-19. With the decision of AEMPS, the tria...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
• First study of Allocetra TM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis 1 , and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOB...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...